drug
as of 2026-07-01Galantamine
galantamine
MeSH D005702
at a glance
small molecule
Pre-approval / investigational in the US
Developed by University of Maryland, Baltimore County
9 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Trials
9
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Effects of Galantamine on Cognition
NCT01100775Phase 2Completed
Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
NCT01012167Phase 2Completed
Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia
NCT00509067Phase 2Completed
Efficacy of Galantamine to Treat Schizophrenia
NCT00232349Phase 4Terminated
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176423Phase 4Completed
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
NCT00161044—Completed
Galantamine for Cognition in People With Schizophrenia
NCT00320736Phase 4Completed
Galantamine for Cognitive Deficits in Schizophrenia
NCT00463879Phase 2, Phase 3Completed
KOLs & investigators
9
A. Eden Evins, MD, MPHKOL score 5
Robert C Smith, M.D., Ph.DKOL score 5
L. Elliot Hong, M.D.KOL score 5
Helge Frieling, Prof., MDKOL score 5
Tony P George, M.D.KOL score 5
William R. McFarlane, M.D.KOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
trial
indication
indication
indication
indication
indication
KOL
A. Eden Evins, MD, MPH
personKOL score 5
Robert C Smith, M.D., Ph.D
personKOL score 5
L. Elliot Hong, M.D.
personKOL score 5
Helge Frieling, Prof., MD
personKOL score 5